Cargando…

Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases

KEY POINTS: Onset of any new cardio-renal-metabolic condition drove substantial increase in health care costs. Overall costs increased by $10,316 (130%) when CKD developed, $6789 (84%) for type 2 diabetes, $21,573 (304%) for atherosclerotic cardiovascular disease, and $36,522 (475%) for heart failur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Gregory A., Amitay, Efrat L., Chatterjee, Satabdi, Steubl, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Nephrology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615376/
https://www.ncbi.nlm.nih.gov/pubmed/37461134
http://dx.doi.org/10.34067/KID.0000000000000212
_version_ 1785129207976689664
author Nichols, Gregory A.
Amitay, Efrat L.
Chatterjee, Satabdi
Steubl, Dominik
author_facet Nichols, Gregory A.
Amitay, Efrat L.
Chatterjee, Satabdi
Steubl, Dominik
author_sort Nichols, Gregory A.
collection PubMed
description KEY POINTS: Onset of any new cardio-renal-metabolic condition drove substantial increase in health care costs. Overall costs increased by $10,316 (130%) when CKD developed, $6789 (84%) for type 2 diabetes, $21,573 (304%) for atherosclerotic cardiovascular disease, and $36,522 (475%) for heart failure. However, as a result of prediagnosis costs being higher as more conditions were present, the percentage increases in costs associated with incidence were lower when more prevalent conditions existed. BACKGROUND: The cardio-renal-metabolic (CRM) syndrome is a constellation of conditions which includes atherosclerotic cardiovascular disease, heart failure (HF), CKD, and type 2 diabetes. The economic consequences of developing each of these comorbidities in the context of the others have not been studied. METHODS: We used the electronic medical records of Kaiser Permanente Northwest to identify 387,985 members aged 18 years or older who had a serum creatinine measured between 2005 and 2017. Patients were followed through 2019. We used a statistical approach that assesses time dependency for continuous measures; the total observation period for each patient was divided into quarters (91-day increments), and each patient contributed a record for every quarter in which they were members of the health plan. CRM status was determined for each quarter. RESULTS: The incremental annualized cost of each of these chronic diseases was similar regardless of which other conditions were present when the new condition developed. Overall costs increased by $10,316 (130%) when CKD developed, $6789 (84%) for type 2 diabetes, $21,573 (304%) for atherosclerotic cardiovascular disease, and $36,522 (475%) for HF. However, as a result of prediagnosis costs being higher as more conditions were present, the percentage increases in costs associated with incidence were lower when more prevalent conditions existed. CONCLUSIONS: Onset of any new CRM condition drove substantial increase in health care costs. Our findings indicate a clear interplay of CRM conditions and emphasize the need for better simultaneous prevention and management of these disease states to reduce the economic burden on health care systems.
format Online
Article
Text
id pubmed-10615376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society of Nephrology
record_format MEDLINE/PubMed
spelling pubmed-106153762023-10-31 Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases Nichols, Gregory A. Amitay, Efrat L. Chatterjee, Satabdi Steubl, Dominik Kidney360 Original Investigation KEY POINTS: Onset of any new cardio-renal-metabolic condition drove substantial increase in health care costs. Overall costs increased by $10,316 (130%) when CKD developed, $6789 (84%) for type 2 diabetes, $21,573 (304%) for atherosclerotic cardiovascular disease, and $36,522 (475%) for heart failure. However, as a result of prediagnosis costs being higher as more conditions were present, the percentage increases in costs associated with incidence were lower when more prevalent conditions existed. BACKGROUND: The cardio-renal-metabolic (CRM) syndrome is a constellation of conditions which includes atherosclerotic cardiovascular disease, heart failure (HF), CKD, and type 2 diabetes. The economic consequences of developing each of these comorbidities in the context of the others have not been studied. METHODS: We used the electronic medical records of Kaiser Permanente Northwest to identify 387,985 members aged 18 years or older who had a serum creatinine measured between 2005 and 2017. Patients were followed through 2019. We used a statistical approach that assesses time dependency for continuous measures; the total observation period for each patient was divided into quarters (91-day increments), and each patient contributed a record for every quarter in which they were members of the health plan. CRM status was determined for each quarter. RESULTS: The incremental annualized cost of each of these chronic diseases was similar regardless of which other conditions were present when the new condition developed. Overall costs increased by $10,316 (130%) when CKD developed, $6789 (84%) for type 2 diabetes, $21,573 (304%) for atherosclerotic cardiovascular disease, and $36,522 (475%) for HF. However, as a result of prediagnosis costs being higher as more conditions were present, the percentage increases in costs associated with incidence were lower when more prevalent conditions existed. CONCLUSIONS: Onset of any new CRM condition drove substantial increase in health care costs. Our findings indicate a clear interplay of CRM conditions and emphasize the need for better simultaneous prevention and management of these disease states to reduce the economic burden on health care systems. American Society of Nephrology 2023-07-18 /pmc/articles/PMC10615376/ /pubmed/37461134 http://dx.doi.org/10.34067/KID.0000000000000212 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Nichols, Gregory A.
Amitay, Efrat L.
Chatterjee, Satabdi
Steubl, Dominik
Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title_full Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title_fullStr Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title_full_unstemmed Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title_short Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
title_sort health care costs associated with the development and combination of cardio-renal-metabolic diseases
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615376/
https://www.ncbi.nlm.nih.gov/pubmed/37461134
http://dx.doi.org/10.34067/KID.0000000000000212
work_keys_str_mv AT nicholsgregorya healthcarecostsassociatedwiththedevelopmentandcombinationofcardiorenalmetabolicdiseases
AT amitayefratl healthcarecostsassociatedwiththedevelopmentandcombinationofcardiorenalmetabolicdiseases
AT chatterjeesatabdi healthcarecostsassociatedwiththedevelopmentandcombinationofcardiorenalmetabolicdiseases
AT steubldominik healthcarecostsassociatedwiththedevelopmentandcombinationofcardiorenalmetabolicdiseases